{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T02:38:39Z","timestamp":1789699119886,"version":"4.0.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12,23]]},"DOI":"10.7759\/cureus.51011","type":"journal-article","created":{"date-parts":[[2023,12,24]],"date-time":"2023-12-24T06:20:19Z","timestamp":1703398819000},"source":"Crossref","is-referenced-by-count":3,"title":["Comparison of the Efficacy of Cisplatin\/Paclitaxel Versus Carboplatin\/Paclitaxel in Improving Survival and Quality of Life in the Advanced Ovarian Cancer Patient Population: A Systematic Review and Meta-Analysis of Randomized Control Trials"],"prefix":"10.7759","author":[{"given":"Marium","family":"Mansoor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Firzah","family":"Shakil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urba","family":"Jalal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatimah","family":"Shahid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maira","family":"Jamal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alishba S","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima A","family":"Abbasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamna","family":"Hijazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamza","family":"Imran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sapna","family":"Hirani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aima","family":"Javaid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahshum","family":"Abu Bakar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul Ahad","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giustino","family":"Varrassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahima","family":"Khatri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satesh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray F","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018, 68:394-424. 10.3322\/caac.21492","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/ijgo.12614","article-title":"Cancer of the ovary, fallopian tube, and peritoneum","volume":"143 Suppl 2","author":"Berek JS","year":"2018","unstructured":"Berek JS, Kehoe ST, Kumar L, Friedlander M. Cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet. 2018, 143 Suppl 2:59-78. 10.1002\/ijgo.12614","journal-title":"Int J Gynaecol Obstet"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.5172\/conu.2012.41.1.5","article-title":"The diagnostic journey of ovarian cancer: a review of the literature and suggestions for practice","volume":"41","author":"Jayde V","year":"2012","unstructured":"Jayde V, Boughton M. The diagnostic journey of ovarian cancer: a review of the literature and suggestions for practice. Contemp Nurse. 2012, 41:5-17. 10.5172\/conu.2012.41.1.5","journal-title":"Contemp Nurse"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21262","article-title":"Global cancer statistics, 2012","volume":"65","author":"Torre LA","year":"2015","unstructured":"Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015, 65:87-108. 10.3322\/caac.21262","journal-title":"CA Cancer J Clin"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/pon.3322","article-title":"A literature review of the social and psychological needs of ovarian cancer survivors","volume":"22","author":"Roland KB","year":"2013","unstructured":"Roland KB, Rodriguez JL, Patterson JR, Trivers KF. A literature review of the social and psychological needs of ovarian cancer survivors. Psychooncology. 2013, 22:2408-18. 10.1002\/pon.3322","journal-title":"Psychooncology"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197812072992301","article-title":"Advanced ovarian adenocarcinoma. A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy","volume":"299","author":"Young RC","year":"1978","unstructured":"Young RC, Chabner BA, Hubbard SP, et al.. Advanced ovarian adenocarcinoma. A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy. N Engl J Med. 1978, 299:1261-6. 10.1056\/NEJM197812072992301","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(84)90594-4","article-title":"Randomised trial comparing two combination chemotherapy regimens (Hexa-CAF vs CHAP-5) in advanced ovarian carcinoma","volume":"2","author":"Neijt JP","year":"1984","unstructured":"Neijt JP, ten Bokkel Huinink WW, van der Burg ME, et al.. Randomised trial comparing two combination chemotherapy regimens (Hexa-CAF vs CHAP-5) in advanced ovarian carcinoma. Lancet. 1984, 2:594-600. 10.1016\/s0140-6736(84)90594-4","journal-title":"Lancet"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.303.6807.884","article-title":"Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Advanced Ovarian Cancer Trialists Group","volume":"303","year":"1991","unstructured":"Chemotherapy in advanced ovarian cancer. an overview of randomised clinical trials. Advanced Ovarian Cancer Trialists Group. BMJ. 1991, 303:884-93. 10.1136\/bmj.303.6807.884","journal-title":"BMJ"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199601043340101","article-title":"Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer","volume":"334","author":"McGuire WP","year":"1996","unstructured":"McGuire WP, Hoskins WJ, Brady MF, et al.. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996, 334:1-6. 10.1056\/NEJM199601043340101","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/92.9.699","article-title":"Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results","volume":"92","author":"Piccart MJ","year":"2000","unstructured":"Piccart MJ, Bertelsen K, James K, et al.. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst. 2000, 92:699-708. 10.1093\/jnci\/92.9.699","journal-title":"J Natl Cancer Inst"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/0277-5379(90)90232-i","article-title":"Risks and benefits of cisplatin in ovarian cancer. A quality-adjusted survival analysis","volume":"26","author":"Willemse PH","year":"1990","unstructured":"Willemse PH, van Lith J, Mulder NH, Aalders JG, Bouma J, de Vries EG, Sleijfer DT. Risks and benefits of cisplatin in ovarian cancer. A quality-adjusted survival analysis. Eur J Cancer. 1990, 26:345-52. 10.1016\/0277-5379(90)90232-i","journal-title":"Eur J Cancer"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3109\/02841868909111182","article-title":"A comparison of the toxicity and efficacy of cisplatin and carboplatin in advanced ovarian cancer. The Swons Gynaecological Cancer Group","volume":"28","author":"Adams M","year":"1989","unstructured":"Adams M, Kerby IJ, Rocker I, Evans A, Johansen K, Franks CR. A comparison of the toxicity and efficacy of cisplatin and carboplatin in advanced ovarian cancer. The Swons Gynaecological Cancer Group. Acta Oncol. 1989, 28:57-60. 10.3109\/02841868909111182","journal-title":"Acta Oncol"},{"key":"ref13","article-title":"Role of carboplatin in ovarian cancer. Current results and thoughts for the future","volume":"155","author":"Ozols RF","year":"1992","unstructured":"Ozols RF. Role of carboplatin in ovarian cancer. Current results and thoughts for the future. Acta Obstet Gynecol Scand Suppl. 1992, 155:75-7.","journal-title":"Acta Obstet Gynecol Scand Suppl"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.rec.2021.07.010","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"74","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Rev Esp Cardiol (Engl Ed). 2021, 74:790-9. 10.1016\/j.rec.2021.07.010","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrtlng.2023.04.011","article-title":"Does thiamine supplementation affect heart failure? A systematic review and meta-analysis of randomized control trials","volume":"61","author":"Syed AR","year":"2023","unstructured":"Syed AR, Syed AA, Akram A, et al.. Does thiamine supplementation affect heart failure? A systematic review and meta-analysis of randomized control trials. Heart Lung. 2023, 61:37-45. 10.1016\/j.hrtlng.2023.04.011","journal-title":"Heart Lung"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JA","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019, 366:l4898. 10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins JP","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003, 327:557-60. 10.1136\/bmj.327.7414.557","journal-title":"BMJ"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djg036","article-title":"A randomized clinical trial of cisplatin\/paclitaxel versus carboplatin\/paclitaxel as first-line treatment of ovarian cancer","volume":"95","author":"du Bois A","year":"2003","unstructured":"du Bois A, L\u00fcck HJ, Meier W, et al.. A randomized clinical trial of cisplatin\/paclitaxel versus carboplatin\/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst. 2003, 95:1320-9. 10.1093\/jnci\/djg036","journal-title":"J Natl Cancer Inst"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.02.153","article-title":"Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study","volume":"21","author":"Ozols RF","year":"2003","unstructured":"Ozols RF, Bundy BN, Greer BE, et al.. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2003, 21:3194-200. 10.1200\/JCO.2003.02.153","journal-title":"J Clin Oncol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph17072213","article-title":"Comparing paclitaxel-carboplatin with paclitaxel-cisplatin as the front-line chemotherapy for patients with Figo IIIC serous-type tubo-ovarian cancer","volume":"17","author":"Huang CY","year":"2020","unstructured":"Huang CY, Cheng M, Lee NR, Huang HY, Lee WL, Chang WH, Wang PH. Comparing paclitaxel-carboplatin with paclitaxel-cisplatin as the front-line chemotherapy for patients with Figo IIIC serous-type tubo-ovarian cancer. Int J Environ Res Public Health. 2020, 17:2213. 10.3390\/ijerph17072213","journal-title":"Int J Environ Res Public Health"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.17.3084","article-title":"Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer","volume":"18","author":"Neijt JP","year":"2000","unstructured":"Neijt JP, Engelholm SA, Tuxen MK, et al.. Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol. 2000, 18:3084-92. 10.1200\/JCO.2000.18.17.3084","journal-title":"J Clin Oncol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.4067","article-title":"Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin\/paclitaxel versus carboplatin\/paclitaxel","volume":"24","author":"Greimel ER","year":"2006","unstructured":"Greimel ER, Bjelic-Radisic V, Pfisterer J, Hilpert F, Daghofer F, du Bois A. Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin\/paclitaxel versus carboplatin\/paclitaxel. J Clin Oncol. 2006, 24:579-86. 10.1200\/JCO.2005.02.4067","journal-title":"J Clin Oncol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14092230","article-title":"Worldwide burden, risk factors, and temporal trends of ovarian cancer: a global study","volume":"14","author":"Huang J","year":"2022","unstructured":"Huang J, Chan WC, Ngai CH, et al.. Worldwide burden, risk factors, and temporal trends of ovarian cancer: a global study. Cancers (Basel). 2022, 14:2230. 10.3390\/cancers14092230","journal-title":"Cancers (Basel)"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21254","article-title":"Cancer statistics, 2015","volume":"65","author":"Siegel RL","year":"2015","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015, 65:5-29. 10.3322\/caac.21254","journal-title":"CA Cancer J Clin"},{"key":"ref25","article-title":"Treatment algorithm in patients with ovarian cancer","volume":"12","author":"Vergote I","year":"2020","unstructured":"Vergote I, Denys H, De Greve J, et al.. Treatment algorithm in patients with ovarian cancer. Facts Views Vis Obgyn. 2020, 12:227-39.","journal-title":"Facts Views Vis Obgyn"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-019-02214-9","article-title":"A systematic review of quality of life research in medicine and health sciences","volume":"28","author":"Haraldstad K","year":"2019","unstructured":"Haraldstad K, Wahl A, Anden\u00e6s R, et al.. A systematic review of quality of life research in medicine and health sciences. Qual Life Res. 2019, 28:2641-50. 10.1007\/s11136-019-02214-9","journal-title":"Qual Life Res"},{"key":"ref27","article-title":"Progression-free survival in advanced ovarian cancer: a Canadian review and expert panel perspective","volume":"18 Suppl 2","author":"Oza AM","year":"2011","unstructured":"Oza AM, Castonguay V, Tsoref D, et al.. Progression-free survival in advanced ovarian cancer: a Canadian review and expert panel perspective. Curr Oncol. 2011, 18 Suppl 2:S20-7.","journal-title":"Curr Oncol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.18939","article-title":"Assessment of progression-free survival as a surrogate end point of overall survival in first-line treatment of ovarian cancer: a systematic review and meta-analysis","volume":"3","author":"Paoletti X","year":"2020","unstructured":"Paoletti X, Lewsley LA, Daniele G, et al.. Assessment of progression-free survival as a surrogate end point of overall survival in first-line treatment of ovarian cancer: a systematic review and meta-analysis. JAMA Netw Open. 2020, 3:e1918939. 10.1001\/jamanetworkopen.2019.18939","journal-title":"JAMA Netw Open"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-021-06735-3","article-title":"Assessment of quality of life among advanced ovarian cancer patients in a tertiary care hospital in India","volume":"30","author":"Sarkar S","year":"2022","unstructured":"Sarkar S, Sahoo PK, Pal R, et al.. Assessment of quality of life among advanced ovarian cancer patients in a tertiary care hospital in India. Support Care Cancer. 2022, 30:3371-8. 10.1007\/s00520-021-06735-3","journal-title":"Support Care Cancer"},{"key":"ref30","article-title":"Health-related quality of life during sequential chemotherapy with carboplatin followed by weekly paclitaxel in advanced ovarian cancer: a multicenter phase ii study of the North Eastern German Society of Gynecological Oncology","volume":"32","author":"Richter R","year":"2012","unstructured":"Richter R, Oskay-Oezcelik G, Chekerov R, et al.. Health-related quality of life during sequential chemotherapy with carboplatin followed by weekly paclitaxel in advanced ovarian cancer: a multicenter phase ii study of the North Eastern German Society of Gynecological Oncology. Anticancer Res. 2012, 32:3969-76.","journal-title":"Anticancer Res"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.2001.6199","article-title":"Quality of life in ovarian cancer patients receiving chemotherapy","volume":"81","author":"Lakusta CM","year":"2001","unstructured":"Lakusta CM, Atkinson MJ, Robinson JW, Nation J, Taenzer PA, Campo MG. Quality of life in ovarian cancer patients receiving chemotherapy. Gynecol Oncol. 2001, 81:490-5. 10.1006\/gyno.2001.6199","journal-title":"Gynecol Oncol"},{"key":"ref32","article-title":"Carboplatin\/paclitaxel induction in ovarian cancer: the finer points","volume":"32","author":"Boyd LR","year":"2018","unstructured":"Boyd LR, Muggia FM. Carboplatin\/paclitaxel induction in ovarian cancer: the finer points. Oncology (Williston Park). 2018, 32:418-20, 422-4.","journal-title":"Oncology (Williston Park)"},{"key":"ref33","article-title":"Carboplatin versus cisplatin in ovarian cancer","volume":"22","author":"Alberts DS","year":"1995","unstructured":"Alberts DS. Carboplatin versus cisplatin in ovarian cancer. Semin Oncol. 1995, 22:88-90.","journal-title":"Semin Oncol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-07802-y","article-title":"Chemotherapy-induced nausea and vomiting (CINV) with carboplatin plus pemetrexed or carboplatin plus paclitaxel in patients with lung cancer: a propensity score-matched analysis","volume":"21","author":"Hayashi T","year":"2021","unstructured":"Hayashi T, Shimokawa M, Matsuo K, Iihara H, Kawada K, Nakano T, Egawa T. Chemotherapy-induced nausea and vomiting (CINV) with carboplatin plus pemetrexed or carboplatin plus paclitaxel in patients with lung cancer: a propensity score-matched analysis. BMC Cancer. 2021, 21:74. 10.1186\/s12885-021-07802-y","journal-title":"BMC Cancer"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2011.256","article-title":"Carboplatin-paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancer","volume":"105","author":"Lee CK","year":"2011","unstructured":"Lee CK, Gurney H, Brown C, et al.. Carboplatin-paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancer. Br J Cancer. 2011, 105:360-5. 10.1038\/bjc.2011.256","journal-title":"Br J Cancer"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.3892\/or.7.3.639","article-title":"Significance of pretreatment serum hemoglobin and survival in epithelial ovarian cancer","volume":"7","author":"Obermair A","year":"2000","unstructured":"Obermair A, Petru E, Windbichler G, et al.. Significance of pretreatment serum hemoglobin and survival in epithelial ovarian cancer. Oncol Rep. 2000, 7:639-44. 10.3892\/or.7.3.639","journal-title":"Oncol Rep"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1183","article-title":"Investigating causes of heterogeneity in systematic reviews","volume":"21","author":"Glasziou PP","year":"2002","unstructured":"Glasziou PP, Sanders SL. Investigating causes of heterogeneity in systematic reviews. Stat Med. 2002, 21:1503-11. 10.1002\/sim.1183","journal-title":"Stat Med"},{"key":"ref38","article-title":"[Prolonged use of paclitaxel for platinum-refractory ovarian cancer--brief report]","volume":"28","author":"Tanaka H","year":"2001","unstructured":"Tanaka H, Konishi Y, Saito H. [Prolonged use of paclitaxel for platinum-refractory ovarian cancer--brief report]. Gan To Kagaku Ryoho. 2001, 28:403-5.","journal-title":"Gan To Kagaku Ryoho"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-015-2820-8","article-title":"Drug fever after cancer chemotherapy is most commonly observed on posttreatment days 3 and 4","volume":"24","author":"Ogawara D","year":"2016","unstructured":"Ogawara D, Fukuda M, Ueno S, et al.. Drug fever after cancer chemotherapy is most commonly observed on posttreatment days 3 and 4. Support Care Cancer. 2016, 24:615-9. 10.1007\/s00520-015-2820-8","journal-title":"Support Care Cancer"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1007\/BF01262572","article-title":"Changes in self-concept and body image during alopecia induced cancer chemotherapy","volume":"5","author":"M\u00fcnstedt K","year":"1997","unstructured":"M\u00fcnstedt K, Manthey N, Sachsse S, Vahrson H. Changes in self-concept and body image during alopecia induced cancer chemotherapy. Support Care Cancer. 1997, 5:139-43. 10.1007\/BF01262572","journal-title":"Support Care Cancer"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11253","article-title":"Fatigue in ovarian carcinoma patients: a neglected issue?","volume":"97","author":"Holzner B","year":"2003","unstructured":"Holzner B, Kemmler G, Meraner V, et al.. Fatigue in ovarian carcinoma patients: a neglected issue?. Cancer. 2003, 97:1564-72. 10.1002\/cncr.11253","journal-title":"Cancer"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jand.2022.05.014","article-title":"Dietary practices after primary treatment for ovarian cancer: a qualitative analysis from the OPAL study","volume":"122","author":"Johnston EA","year":"2022","unstructured":"Johnston EA, Ekberg S, Jennings B, Jagasia N, van der Pols JC, Webb PM. Dietary practices after primary treatment for ovarian cancer: a qualitative analysis from the OPAL study. J Acad Nutr Diet. 2022, 122:1607-1628.e12. 10.1016\/j.jand.2022.05.014","journal-title":"J Acad Nutr Diet"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1111\/jsr.13510","article-title":"Insomnia and circadian sleep disorders in ovarian cancer: Evaluation and management of underestimated modifiable factors potentially contributing to morbidity","volume":"31","author":"Palagini L","year":"2022","unstructured":"Palagini L, Miniati M, Massa L, Folesani F, Marazziti D, Grassi L, Riemann D. Insomnia and circadian sleep disorders in ovarian cancer: Evaluation and management of underestimated modifiable factors potentially contributing to morbidity. J Sleep Res. 2022, 31:e13510. 10.1111\/jsr.13510","journal-title":"J Sleep Res"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.34067\/KID.0005622020","article-title":"Hypomagnesemia in the cancer patient","volume":"2","author":"Workeneh BT","year":"2021","unstructured":"Workeneh BT, Uppal NN, Jhaveri KD, Rondon-Berrios H. Hypomagnesemia in the cancer patient. Kidney360. 2021, 2:154-66. 10.34067\/KID.0005622020","journal-title":"Kidney360"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-017-3392-8","article-title":"Electrolyte disorders with platinum-based chemotherapy: mechanisms, manifestations and management","volume":"80","author":"Oronsky B","year":"2017","unstructured":"Oronsky B, Caroen S, Oronsky A, et al.. Electrolyte disorders with platinum-based chemotherapy: mechanisms, manifestations and management. Cancer Chemother Pharmacol. 2017, 80:895-907. 10.1007\/s00280-017-3392-8","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/205724-comparison-of-the-efficacy-of-cisplatinpaclitaxel-versus-carboplatinpaclitaxel-in-improving-survival-and-quality-of-life-in-the-advanced-ovarian-cancer-patient-population-a-systematic-review-and-meta-analysis-of-randomized-control-trials","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:11:04Z","timestamp":1707509464000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/205724-comparison-of-the-efficacy-of-cisplatinpaclitaxel-versus-carboplatinpaclitaxel-in-improving-survival-and-quality-of-life-in-the-advanced-ovarian-cancer-patient-population-a-systematic-review-and-meta-analysis-of-randomized-control-trials"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,23]]},"references-count":45,"URL":"https:\/\/doi.org\/10.7759\/cureus.51011","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12,23]]}}}